0001104659-23-023768.txt : 20230221 0001104659-23-023768.hdr.sgml : 20230221 20230221160130 ACCESSION NUMBER: 0001104659-23-023768 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230216 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230221 DATE AS OF CHANGE: 20230221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 23647986 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 tm237425d1_8k.htm FORM 8-K
0000744218 false 0000744218 2023-02-16 2023-02-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 16, 2023

 

 

 

Celldex Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-15006   13-3191702
(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

Perryville III Building, 53 Frontage Road, Suite 220

Hampton, New Jersey 08827

(Address of Principal Executive Offices) (Zip Code)

 

(908) 200-7500

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.001   CLDX   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Upon the recommendation of the nominating and corporate governance committee of Celldex Therapeutics, Inc. (the “Company”), Rita Jain, M.D. was appointed as a member of our Board of Directors (the “Board”) on February 16, 2023. Dr. Jain has served on the Board of Directors of Provention Bio, Inc since January 2023, as a member of the Supervisory Board of AM-Pharma B.V. since 2020 and on the Board of Directors of ChemoCentryx, Inc. from 2019 until its acquisition by Amgen in 2022. From 2021 to 2022, Dr. Jain served as Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc. and in 2021 served as Chief Medical Officer of Immunovant, Inc. Additionally, since August 2021, Dr. Jain has served as Chief Executive Officer of Heartwood Biopharma Group, a private consulting group. From 2017 to 2019, Dr. Jain was Senior Vice President and Chief Medical Officer at Akebia Therapeutics, Inc. From 2013 to 2016, Dr. Jain was a Vice President in Clinical Development at AbbVie Inc., including Men’s and Women’s Health and Metabolic Development. Dr. Jain also held various leadership roles at Abbott Laboratories from 2003 through 2012, including as Divisional Vice President of Pain, Respiratory and Metabolic Disease Development. Dr. Jain received her B.S. degree in biology from the Long Island University, and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain will hold this position until the next annual meeting of the Company’s stockholders or until her successor is elected and qualified, subject to her earlier resignation or removal.

 

Dr. Jain has no family relationships with any of the Company’s directors or executive officers, and she has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Dr. Jain will participate in the Company’s standard non-employee director compensation plan. In connection with her appointment to the Board, Dr. Jain will receive an initial option grant to purchase 17,100 shares of the Company’s common stock that will vest one third on the first, second and third anniversaries of the date of grant.

 

Item 7.01. Regulation FD Disclosure.

 

On February 16, 2023, the Company issued a press release announcing the appointment of Dr. Jain. A copy of the press release is furnished as Exhibit 99.1 hereto. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description 
99.1   Press Release, dated February 16, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Celldex Therapeutics, Inc.
     
Date: February 21, 2023 By:  /s/ Sam Martin
    Sam Martin
    Senior Vice President and Chief Financial Officer

 

-3-

 

 EX-99.1 2 tm237425d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

 

HAMPTON, N.J., February 16, 2023 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company’s Board of Directors.

 

“We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company’s trajectory,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “Dr. Jain’s deep background in drug development strongly complements our Board’s skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development.”

 

Dr. Jain added, “I am excited to join Celldex, whose emerging data suggests that barzolvolimab has significant potential to open a new class of therapeutics to treat difficult diseases across a broad spectrum of conditions in allergy, inflammation and immunology. I look forward to working with Celldex’s outstanding team to advance the Company’s mission."

 

Dr. Jain is a board-certified rheumatologist. She previously served as Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc., Chief Medical Officer of Immunovant, Inc. and prior to that, Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc. Before joining Akebia, Dr. Jain served as Vice President of Men's and Women's Health and Metabolic Development at AbbVie, Inc. and in various leadership roles at Abbott Laboratories, including Divisional Vice President. Prior to her time at Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle, which was acquired by Pharmacia and, later, Pfizer. She was responsible for leading the design and execution of multiple late-stage programs, including for Orilissa® and Oriahnn® and has also led programs across a diverse set of therapeutic areas, including immunology, inflammation, pain and nephrology. Earlier in her career, Dr. Jain served as a faculty member at North Shore University Hospital in New York. Dr. Jain currently serves as a member of the Board of Directors for Provention Bio, Inc. and serves on the supervisory board of AM Pharma. She previously served on the Board of Directors of ChemoCentryx, Inc. until its acquisition by Amgen. Dr. Jain received her M.D. from the State University of New York at Stony Brook School of Medicine and her B.S. in Biology from Long Island University.

 

Orilissa® and Oriahnn® are registered trademarks of AbbVie, Inc.

 

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

 

 

 

 

Forward Looking Statement

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the effects of the outbreak of COVID-19 on our business and results of operations; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

 

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

 

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

scavanaugh@celldex.com

 

Patrick Till

Meru Advisors

(484) 788-8560

ptill@meruadvisors.com

 

 

 

 EX-101.SCH 3 cldx-20230216.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cldx-20230216_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cldx-20230216_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm237425d1_ex99-1img001.jpg GRAPHIC begin 644 tm237425d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 16, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 16, 2023
Entity File Number 000-15006
Entity Registrant Name Celldex Therapeutics, Inc.
Entity Central Index Key 0000744218
Entity Tax Identification Number 13-3191702
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Perryville III Building, 53 Frontage Road, Suite 220
Entity Address, City or Town Hampton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08827
City Area Code 908
Local Phone Number 200-7500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.001
Trading Symbol CLDX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm237425d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000744218 2023-02-16 2023-02-16 iso4217:USD shares iso4217:USD shares 0000744218 false 8-K 2023-02-16 Celldex Therapeutics, Inc. DE 000-15006 13-3191702 Perryville III Building, 53 Frontage Road, Suite 220 Hampton NJ 08827 908 200-7500 false false false false Common Stock, par value $.001 CLDX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://celldextherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm237425d1_8k.htm cldx-20230216.xsd cldx-20230216_lab.xml cldx-20230216_pre.xml tm237425d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm237425d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm237425d1_8k.htm" ] }, "labelLink": { "local": [ "cldx-20230216_lab.xml" ] }, "presentationLink": { "local": [ "cldx-20230216_pre.xml" ] }, "schema": { "local": [ "cldx-20230216.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CLDX", "nsuri": "http://celldextherapeutics.com/20230216", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm237425d1_8k.htm", "contextRef": "From2023-02-16to2023-02-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://celldextherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm237425d1_8k.htm", "contextRef": "From2023-02-16to2023-02-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://celldextherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-023768-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-023768-xbrl.zip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end